Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, and Selonsertib & Cenicriviroc), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy) – Global Opportunity Analysis and Industry Forecast 2025

Press Release

The report on “Non-Alcoholic Steatohepatitis (NASH) Market” will help Major Players and the new entrants to understand scrutinize the market in detail. This information will encourage the Major Players to decide their business strategy and achieve proposed business aims.

The global non-alcoholic steatohepatitis (NASH) market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.

Top Companies Covered in this Report:
Allergan plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, Shire Plc.

Get sample copy of “Non-Alcoholic Steatohepatitis (NASH) Market” at:

The nonalcoholic steatohepatitis (NASH) market is expected to show double digit growth during the forecast period owing to increase in prevalence of NASH across the world, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics in the developing region. Furthermore, rise in prevalence of diabetes & obesity and growth in demand for ideal therapeutics are expected to influence the market growth in near future. On the other side, lack of diagnostic technologies for NASH limit the growth of the market.

The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits for Stakeholders:

The report provides an extensive analysis of the current and emerging Non-Alcoholic Steatohepatitis (NASH) market trends.
It offers quantitative analysis, which assists to identify the prevailing market opportunities.
Comprehensive analysis of factors that drive and restrict the market growth are provided in the report.
Competitive intelligence of leading players of Non-Alcoholic Steatohepatitis (NASH) helps understand the competitive scenario across geographies.

Have any query? Enquire about report at:

Fundamentals of Table of Content:

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Non-Alcoholic Steatohepatitis (NASH) Market Size
2.2 Non-Alcoholic Steatohepatitis (NASH) Growth Trends by Regions
2.3 Industry Trends

3 Market Share by Key Players
3.1 Non-Alcoholic Steatohepatitis (NASH) Market Size by Manufacturers
3.2 Non-Alcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
3.3 Key Players Non-Alcoholic Steatohepatitis (NASH) Product/Solution/Service
3.4 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Sales by Product
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Revenue by Product
4.3 Non-Alcoholic Steatohepatitis (NASH) Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Breakdown Data by End User

Get Complete Report at:

Contact Us:                                          
Call: +912067274191
Email: [email protected]

About Premiummarketinsights: is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.